Medtecs International Corporation Ltd. 546

Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain. This might have investors contemplating their next move.

Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.

Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.

Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s

Eli Lilly's (LLY) new obesity data support a broader drug portfolio beyond tirzepatide, or TZP, UBS

Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, is proud to kick off its annual Breast Cancer Action Month initiative. For the seventh consecutive year, Curaleaf is running its national at-register Round Up campaign, giving customers in every store the chance to round up their purchase, or donate $1 or $5, at checkout. This year's proceeds will support Impact One Breast Cancer Foundation, a nonprofi

Bond yields hit their highest level in two decades, pressuring blue chip dividend stocks and weighing on the broader market, today, Oct. 1, 2026.

With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.

Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.

Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).

CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.

Regulatory setback hits Trulieve Cannabis The decision by DEA Chief Judge Derek Julius to pause the federal cannabis rescheduling case immediately weighed on sector sentiment, with Trulieve Cannabis (TRLV) moving lower as investors reassessed expectations around the timing of regulatory change. That pause landed on a stock that had already cooled off in the near term. Trulieve Cannabis has dropped about 12% on a 1 day share price basis and is down 13% over the past week, yet still shows a 25%...

Like runners striving to break from the pack, a slew of wearables companies are competing for share of consumers’ health and fitness tracking habits. With Apple latest heart-rate focused updates to its best-selling Apple Watch and an upcoming Health app redesign, it’s hoping to expand an already impressive lead. Users will be able to calculate their “health age”—a comparison of their overall health measurements with their actual age—as well as a Readiness score that gauges capacity for strenuous activity.

Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program. REZ

WOIPPY, France, October 01, 2026--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical research, s raising its revenue guidance for the financial year ending 31 December 2026. Based on the commercial, operational and accounting information available as of the date of this press release, the Company now expects revenue to be between €13.5

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September

Strasbourg, France, October 1, 2026, 5:45 pm CET — Transgene (Euronext Paris: TNG), a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence together with a portfolio of virus-based candidates, today announced that its management team will meet institutional investors during the upcoming edition of Investor Access Event (by Investor Access), on October 6, 2026, in Paris. Organized by Investor Access, these events